

EXAMINER'S AMENDMENT

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Zeev Pearl on 12/16/2010, 01/04/2011 and 01/20/2011.

The application has been amended as follows:

In claim 32, line 9, after diagnostics, delete ", hydrogen or a drug" and insert --- or a drug to be targeted to PNOM-cells ---

In claim 35, line 5, after is, delete "hydroxyl or"

In claim 37, line 5, after is, delete "selected from ^{18}F and OH" and insert --- ^{18}F ---

In claim 40, line 5, after is, delete "selected from hydrogen, ^{18}F and OH" and insert --- ^{18}F ---

In claim 42, line 7, after a, delete "fluorescent label" and insert ---NH-dansyl and fluorescent---

In claim 46, line 6, after or, delete " F^{19} " and insert --- ^{19}F ---

In claim 50, line 1, after any, delete "of the formula III, IV, V, VI, VII, IX, X, XI, XIII, or XIV" and insert ---one of claims 32, 35, 37, 40, 42, 44, 46, 47 or 49 ---

Cancel claims 28-31, 36, 41, 45, and 55-69.

Reasons for allowance

2. The following is an examiner's statement of reasons for allowance: The closest prior art is Ziv Ilan (WO-02/46147) discloses compounds that bind selectively to cells undergoing perturbations and alterations comprising heterocyclic compounds, but fails to specifically disclose or render obvious the combination of substituents (compounds represented by formula II-III, V-VI, IX-XI and XIII-XIV) set forth in the instant claims. The claimed subject matter is not taught or suggested by the cited reference and thus, the claimed subject matter is considered to be novel and patentably distinct over the prior art of the record. .

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to JAGADISHWAR R. SAMALA whose telephone number is (571)272-9927. The examiner can normally be reached on 8.30 A.M to 5.00 P.M.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael G. Hartley can be reached on (571)272-0616. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/J. R. S./
Examiner, Art Unit 1618

/Michael G. Hartley/
Supervisory Patent Examiner, Art
Unit 1618